Category: Oncotarget

Oncotarget News

Oncotarget Sponsors Open Access Team in 2025 Ride for Roswell

June 10, 2025

Impact Journals, the publisher of Oncotarget, is once again proudly sponsoring the Open Access Team in the annual Ride for Roswell.BUFFALO, NY — June 10, 2025 — The Ride for Roswell,... read more

Oncotarget

Cigarette Smoke and DNA Repair Deficiency Drive Lung Cancer Development

June 9, 2025

In this study, we investigated the interplay between cigarette smoke, DNA damage and repair, focusing on the Nucleotide Excision Repair (NER) protein Xeroderma Pigmentosum Group C (XPC).”BUFFALO, NY - June... read more

Oncotarget

Targeting PCNA-Androgen Receptor Interaction Suppresses Prostate Cancer Cell Growth

June 4, 2025

This finding implicates that targeting PCNA/AR interaction could be an innovative strategy for therapy against CRPC.”BUFFALO, NY - June 4, 2025 – A new research paper was published in Volume... read more

Oncotarget

Blocking PRDX1 Protein May Improve Chemotherapy Response in Ovarian Cancer

June 3, 2025

The data suggest that PRDX1 can predict responses to chemotherapy, and targeting PRDX1 could be a viable strategy to improve the efficacy of platinum chemotherapy.”BUFFALO, NY - June 3, 2025 –... read more

Oncotarget

Immune Side Effects of Liver Cancer Therapy Studied in Latin American Patients

May 23, 2025

This study provides valuable insights into the incidence and impact of irAEs in patients with HCC treated with the combination of atezolizumab and bevacizumab in real-world practice.”BUFFALO, NY - May... read more

Oncotarget

Combining Radiation and Immunotherapy Shows Promise for Bladder Cancer

May 21, 2025

The synergistic mechanisms of radiation therapy and immunotherapy have demonstrated significant potential for enhancing the outcomes of cancer treatment."BUFFALO, NY - May 21, 2025 – A new review was published in... read more

Oncotarget

New Ultra-Sensitive DNA Blood Test for Detecting Residual Cancer in B-cell Lymphoma Patients

May 19, 2025

Collectively, the data presented here suggest that the PhasED-Seq-based MRD assay is accurate and reproducible, making it appropriate for use in the clinical setting for individuals with B-cell malignancies."BUFFALO,... read more

Oncotarget

Blood Type A Identified as Potential Breast Cancer Risk Factor

May 14, 2025

This study highlights the potential of blood type A as a risk factor for breast cancer compared to blood type O."BUFFALO, NY - May 14, 2025 – A new review paper... read more